AR086185A1 - ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION - Google Patents

ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION

Info

Publication number
AR086185A1
AR086185A1 ARP120101348A AR086185A1 AR 086185 A1 AR086185 A1 AR 086185A1 AR P120101348 A ARP120101348 A AR P120101348A AR 086185 A1 AR086185 A1 AR 086185A1
Authority
AR
Argentina
Prior art keywords
population
hcv infection
specific patient
combined therapy
formula
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Federico Mensa
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to ARP120101348 priority Critical patent/AR086185A1/en
Publication of AR086185A1 publication Critical patent/AR086185A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de infección viral por hepatitis C (HCV) o alivio de uno o varios de sus síntomas en un paciente, caracterizado porque comprende la etapa de administración al paciente de una combinación terapéutica que comprende: (a) un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde B es un resto de fórmula (3); L0 es MeO-; L1 es Br; y R2 es un resto de fórmula (4); (b) un compuesto de la fórmula (2) o de sus sales farmacéuticamente aceptables; y opcionalmente (c) ribavirina; y en donde el paciente tiene una enfermedad hepática compensada.Claim 1: A method of treating hepatitis C viral infection (HCV) or alleviating one or more of its symptoms in a patient, characterized in that it comprises the stage of administration to the patient of a therapeutic combination comprising: (a) a compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein B is a residue of formula (3); L0 is MeO-; L1 is Br; and R2 is a residue of formula (4); (b) a compound of the formula (2) or its pharmaceutically acceptable salts; and optionally (c) ribavirin; and where the patient has a compensated liver disease.

ARP120101348 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION AR086185A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP120101348 AR086185A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP120101348 AR086185A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION

Publications (1)

Publication Number Publication Date
AR086185A1 true AR086185A1 (en) 2013-11-27

Family

ID=50185255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101348 AR086185A1 (en) 2012-04-19 2012-04-19 ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION

Country Status (1)

Country Link
AR (1) AR086185A1 (en)

Similar Documents

Publication Publication Date Title
EA201991174A1 (en) COMBINATION OF TWO ANTIVIRAL DRUGS FOR TREATMENT OF HEPATITIS C
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
ECSP14013189A (en) INHIBITORS OF THE REPLICATION OF VIRUSES OF THE FLU
UY33897A (en) HEPATITIS C VIRUS INHIBITORS
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
DOP2014000049A (en) METHODS FOR HCV TREATMENT THAT INCLUDE AT LEAST TWO DIRECT ACTION ANTIVIRAL AGENTS (DAAAS) AND RIBAVIRINE BUT NOT INTERFERONED
RU2013119607A (en) POLYCYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR APPLICATION FOR TREATMENT OF VIRAL DISEASES
EA201490419A1 (en) COMPOUNDS FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCIAL VIRAL DISEASE
EA201200096A1 (en) PHARMACEUTICAL COMPOSITION OF THE HYPATITIS VIRUS PROTEASE INHIBITOR INHIBITOR
EA201290576A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
UY32124A (en) COMBINED THERAPY TO TREAT HCV INFECTION
EA201290053A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
ECSP099792A (en) NEW INHIBITING PEPTIDES FOR HEPATITIS C VIRUS REPLICATION
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
RU2015114543A (en) HEPATITIS TREATMENT METHODS
EA201391685A1 (en) HEPATITIS C VIRUS INHIBITORS
ECSP13012551A (en) COMBINATION THERAPY TO TREAT HCV INFECTION.
BR112014013972A8 (en) hcv inhibitors nssa
DOP2014000030A (en) PROCEDURES FOR THE MANUFACTURE OF USEFUL DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS
EA201170605A1 (en) CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE
CO7131387A2 (en) Compositions and methods of oligonucleotide chelate complex-polypeptides
RU2015114566A (en) HEPATITIS TREATMENT METHODS
AR091421A1 (en) COMBINED THERAPEUTIC COMPOSITION TO TREAT HEPATITIS C
EA201692514A1 (en) PHARMACEUTICAL COMPOSITIONS ON THE BASIS OF SOFOSBUVIR AND RIBAVIRIN WITH MODIFIED FREEDOM

Legal Events

Date Code Title Description
FB Suspension of granting procedure